This article is more than 5 years old. Information may no longer be current.

Cellceutix developing antibiotic compound for ocular infection

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Cellceutix announced that it is currently conducting experiments on brilacidin, an antibiotic compound for the treatment of ophthalmic infections, including keratitis and conjunctivitis, according to a press release.

Prior studies have demonstrated the safety, tolerability and broad activity of brilacidin against gram-positive and gram-negative pathogens, including drug-sensitive and drug-resistant clinical isolate strains of ocular infections.

Also, previous pharmacokinetic studies showed that brilacidin has a high residence time on the surface of the eye with negligible systemic exposure, meaning that effective therapeutic concentrations of the antibiotic can be maintained in the eye with infrequent treatments, according to the release.